Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
Now Viewing
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Related Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
